Trials / Not Yet Recruiting
Not Yet RecruitingNCT06691360
AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 87 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of AK137 in patients with advanced malignant tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK137 | IV infusion, specified dose on specified days. |
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2027-05-01
- Completion
- 2027-08-01
- First posted
- 2024-11-15
- Last updated
- 2024-11-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06691360. Inclusion in this directory is not an endorsement.